LINE250516P30000
- 0.00
- 0.000.00%
Lineage Newsroom
Truist Financial Maintains Lineage(LINE.US) With Buy Rating, Maintains Target Price $65
Evercore Maintains Lineage(LINE.US) With Hold Rating, Cuts Target Price to $59
Lineage, Inc. Receives Buy Rating Amid Strategic Acquisition and Growth Prospects
Scotiabank Downgrades Lineage(LINE.US) to Hold Rating, Cuts Target Price to $56
Scotiabank Downgrades Lineage to Sector Perform From Sector Outperform, Adjusts Price Target to $56 From $74
Barclays Initiates Lineage(LINE.US) With Buy Rating, Announces Target Price $59
Lineage Initiated at Overweight by Barclays
Lineage Analyst Ratings
Maxim Group Reaffirms Their Buy Rating on Lineage Therap (LCTX)
Truist Financial Maintains Lineage(LINE.US) With Buy Rating, Maintains Target Price $65
Lineage, Inc. (LINE) Receives a Buy From Truist Financial
Morgan Stanley Maintains Lineage(LINE.US) With Buy Rating, Cuts Target Price to $75
Lineage Is Maintained at Overweight by Morgan Stanley
Morgan Stanley Maintains Overweight on Lineage, Lowers Price Target to $75
Citi Maintains Lineage(LINE.US) With Hold Rating, Maintains Target Price $64
Lineage Price Target Announced at $64.00/Share by Citigroup
Lineage Initiated at Neutral by Citigroup
Lineage Analyst Ratings
Citi Initiates Lineage(LINE.US) With Hold Rating, Announces Target Price $64
Lineage Cell Therapeutics Analyst Ratings